A new potential mRNA vaccine that delivers instructions for making two key HIV proteins has been tested in mice and rhesus macaques.
List view / Grid view
US National Institutes of Health (NIH)
In this article, Drug Target Review’s Victoria Rees explores a new screening platform that assesses the biological activity of molecules to identify potential drugs. Using their new technique, researchers from the US National Institutes of Health (NIH) identified potential COVID-19 therapeutics.
Two groups of infant rhesus macaques received one of two potential COVID-19 vaccines, which were shown to elicit high levels of neutralising antibodies.
The experimental drug TEMPOL has demonstrated antiviral activity against COVID-19 in a pre-clinical study in cell cultures.
An airway-on-a-chip has been used to show that amodiaquine inhibits SARS-CoV-2 infection, making it a potential COVID-19 therapeutic.
Researchers have shown that Chroman 1, Emricasan and trans-ISRIB, in combination with polyamines, are effective at protecting induced pluripotent stem cells from stress.
Researchers have developed a stem cell therapy that could treat the damage caused by dementia by launching a repair response.
Researchers have developed their previously created brain organoid to test for potential drugs against Creutzfeldt-Jakob disease (CJD).
The drug MK-4482 decreased viral levels in the lungs of hamsters treated for SARS-CoV-2 infection, researchers have shown.
Although a cure for HIV continues to elude scientists, strategies to control the virus and immunise people are developing at rapid pace. Here, Drug Target Review’s Victoria Rees discusses why researchers are focusing on antibodies as approaches to combat HIV and highlights recent findings from two pre-clinical studies into how…
Researchers have revealed that T cells in blood samples from people who recovered from COVID-19 responded to SARS-CoV-2 variants.
Researchers have shown that SARS-CoV-2 infects mouth cells, which could inform the development of treatments against the oral symptoms of COVID-19.
A study has shown the mosquito protein AEG12 inhibits flaviviruses, the family of viruses that cause yellow fever, dengue and Zika.
NeuroCOVID will be a resource of clinical information and biospecimens from people who experience neurological problems associated with SARS-CoV-2 infection.
Scientists have identified a potential alternative to antibiotics, a nutrient named taurine that helps the microbiome kill invading bacteria.